세계 세포 생존율 분석 시장 - 점유율 분석, 산업 동향, 통계 및 성장 예측(2024-2029년)

The cell viability assay market is valued at USD 1.74 billion in 2024 and is expected to reach USD 2.78 billion by 2029, registering a CAGR of 9.89% over the forecast period.

The COVID-19 pandemic significantly impacted the growth of the cell viability assay market, as most companies focused on developing cell-based therapies for COVID-19 treatment. For instance, according to the study published in Stem Cell Research & Therapy volume in January 2022, stem cell therapy and stem cell-derived organoid models got much attention as a new treatment and research method for COVID-19, and stem cells played a role in the battle against COVID-19. With the increase in the need for stem cell therapies, there was to be an increase in the need for cell viability assays; hence, the market grew during the pandemic. However, as the pandemic has subsided, the studied market is expected to have stable growth during the forecast period of the study.

Factors such as the growing burden of chronic and infectious diseases, rising demand for cell-based assays in research, and increasing focus on developing cell-based therapeutics drive global market growth. Moreover, chronic diseases and conditions are on the rise worldwide, which is expected to further enhance the usage of cell viability assays. As per the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults were living with diabetes worldwide, and the number is expected to reach 643 million by 2030 and 783 million by 2045. As chronic disorders are on the rise, there is a huge demand for assays, which are helping in the faster treatment and timely detection of patients' conditions.

In emerging markets, cancer and heart diseases are becoming the main causes of death due to urbanization, sedentary lifestyles, changing diets, rising obesity levels, and widespread availability of tobacco products. For instance, according to an article published by PubMed Central in March 2022, China is experiencing a greater incidence of cancers. In 2022, there were expected to be approximately 4,820,000 new cancer cases in China, of which the most common is lung cancer. Hence, the high prevalence of chronic diseases such as cancer is expected to boost the adoption of cell viability assays to develop more innovative drugs.

Moreover, developing new cell viability assays to meet the rising demand is also a major factor driving the market growth. For instance, according to an article published by PubMed Central in May 2022, a novel cell viability assay was developed, which can check cellular viability in real-time using supervised machine learning and intracellular dynamic activity data acquired in a label-free, non-invasive, and non-destructive manner. Thus, the rising developments, such as novel cell viability assays, are also expected to boost market growth.

However, the limitations of the assays are expected to impede the market growth.

Cell Viability Assays Market Trends

Stem Cell Research Segment is Estimated to Register A Significant Growth Over the Forecast Period

The stem cell research segment is estimated to register significant growth, owing to the rising R&D activities and funding from various organizations. For instance, in June 2021, the Morrison Government invested USD 180 million in ground-breaking medical research projects around Australia to improve the lives of Australians. The source also stated that the investment was funded through the government's USD 20 billion Medical Research Future Fund, and 106 medical research projects will receive funding to improve health outcomes, including for Australians with cancer, dementia, brain injuries, heart problems, neurofibromatosis, and many others. Thus, the increasing investments in medical research, including stem cell research, are expected to boost the growth of the studied segment.

Technological advancements will play a significant role in the future, with multiple experiments in pluripotent stem cells being the center for exciting growth. For instance, in April 2022, researchers at Osaka University developed a biomaterial using stem cells to reverse intervertebral disk (IVD) degeneration associated with back pain and certain spinal issues. The stem cells were induced into chondrocytes -- cells producing collagen that supports cartilage tissue. Implanting this biomaterial into a rat model of IVD degeneration brought the spinal mechanical properties back to control levels, and this type of innovation will likely fuel market growth in future years.

Companies are raising funds to develop stem cell-based therapies to tackle many diseases. For instance, in January 2022, Cellino Biotech, a cell therapy manufacturing company, raised a USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies to build the first autonomous human cell foundry in 2025. As the applications of stem cell technologies in the treatment of diseases have ultimately increased, the overall adoption rate of cell viability assays worldwide.

Thus, considering all the factors above, such as the rising R&D activities and funding from various organizations, the studied segment is expected to witness high growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America holds a significant share of the cell viability assays market and is expected to witness a similar trend over the forecast period without significant fluctuations. The region is dominating the market due to various factors like the increasing incidences of chronic diseases, rise in cancer cases, rise in government investment initiatives, and high-quality infrastructure for clinical and laboratory research.

The United States is expected to increase its market share in the future, owing to the increased adoption of cancer therapy and the growing burden of cancers in the United States. According to the data in the Cancer Facts & Figures 2022 data published by the American Cancer Society, there would be an estimated 1.9 million new cancer cases in the United States in 2022, out of which 89,010 were expected to be lymphoma and 60,650 cases were expected to be leukemia.

Furthermore, according to the National Institute of Health, in May 2022, the estimated research funding for cancer was USD 7,362 million in the United States in 2021, and it increased to USD 7,644 million in 2022. The high investments in cancer research are also expected to boost the market's future growth.

Moreover, in March 2022, Promega Corporation and FUJIFILM Cellular Dynamics, Inc. announced a strategic collaboration to advance novel assay development for drug discovery. Under a multi-year licensing agreement, FUJIFILM Cellular Dynamics will offer a wide range of custom differentiated iPSCs integrated with Promega biosensor and intracellular bioluminescent reporter capabilities for researchers and scientists to use as part of novel assay development in the drug discovery process.

Furthermore, in the United States, there is a rise in funding for cell-based research, which is also expected to propel the overall growth of the cell viability assay market over the forecast period.

Cell Viability Assays Industry Overview

The cell viability assays market is fragmented and competitive owing to the presence of various small and large market players. Some of the market players are Abcam PLC, Becton Dickinson & Company, Bio-Rad Laboratories, Biotek Instruments, Creative Bioarray, GE Healthcare, Merck KGaA, Perkin Elmer, Promega Corporation, and Thermo Fischer Scientific Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Burden of Chronic and Infectious Diseases
  • 4.2.2 Rising Demand for Cell-based Assays in Research
  • 4.2.3 Increasing Focus on the Development of Cell-based Therapeutics
• 4.3 Market Restraints
  • 4.3.1 Limitations of the Assays
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Buyers/Consumers
  • 4.4.2 Bargaining Power of Suppliers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Product
  • 5.1.1 Consumables
    • 5.1.1.1 Reagents
    • 5.1.1.2 Assay Kits
    • 5.1.1.3 Other Consumables
  • 5.1.2 By Instruments
    • 5.1.2.1 Automated Cell Counters
    • 5.1.2.2 Flow Cytometers
    • 5.1.2.3 Spectrophotometers
    • 5.1.2.4 Other Instruments
• 5.2 By Application
  • 5.2.1 Drug Discovery and Development
  • 5.2.2 Stem Cell Research
  • 5.2.3 Clinical and Diagnostic Applications
  • 5.2.4 Other Applications
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abcam PLC
  • 6.1.2 Becton Dickinson & Company
  • 6.1.3 Bio-Rad Laboratories
  • 6.1.4 Biotek Instruments
  • 6.1.5 Creative Bioarray
  • 6.1.6 GE Healthcare
  • 6.1.7 Merck KGaA
  • 6.1.8 Perkin Elmer
  • 6.1.9 Promega Corporation
  • 6.1.10 Thermo Fischer Scientific Inc.
  • 6.1.11 Canvax Biotech
  • 6.1.12 Creative Bioarray

7 MARKET OPPORTUNITIES AND FUTURE TRENDS